3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
10
Thoracic
2
Sarcoma
1
Other solid neoplasm
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Conditions
Gastrointestinal Stromal Tumors
3
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
9
Gemcitabine
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Paclitaxel
6
Cisplatin
6
Trastuzumab
5
Irinotecan
5
Doxorubicin
5
Docetaxel
5
Peripheral Blood Stem Cell Transplantation
4
Filgrastim
4
Capecitabine
4
poly ICLC
3
pazopanib
3
liposomal doxorubicin
3
durvalumab
3
atezolizumab
3
Therapeutics
3
Taxes
3
Surveys and Questionnaires
3
Radiation
3
Polymerase Chain Reaction
3
Oncolytic Virotherapy
3
Letrozole
3
Injections
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
Flow Cytometry
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Midazolam
×
Sarcoma
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled